Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions

Authors

Ajay Major, University of Chicago
Edward R Scheffer Cliff, Harvard University
Daniel A Ermann, University of Utah
Urshila Durani, Mayo Clinic
David A Russler-Germain, Washington University School of Medicine in St. Louis

Journal

EJHaem

Publication Date

8-1-2022

Volume

3

Issue

3

First Page

930

Last Page

935

Document Type

Open Access Publication

DOI

10.1002/jha2.505

Rights and Permissions

Major, A, Cliff, ERS, Ermann, DA, Durani, U, Russler-Germain, DA. Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. eJHaem. 2022; 3: 930– 935. https://doi.org/10.1002/jha2.505 © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Major, Ajay; Cliff, Edward R Scheffer; Ermann, Daniel A; Durani, Urshila; and Russler-Germain, David A, "Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions." EJHaem. 3, 3. 930 - 935. (2022).
https://digitalcommons.wustl.edu/oa_4/433